Are there any serious side effects of entrectinib?

Entrectinib (Entrectinib) is a targeted therapy drug used to treat some specific types of cancer, such as ROS1 fusion-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. In clinical studies, the side effects of entrectinib are important issues that require attention.

According to clinical study results, the most common side effects of entrectinib (≥20%) include fatigue, constipation, dysgeusia, edema, dizziness, diarrhea, nausea, hypoesthesia, dyspnea, myalgia, cognitive impairment, weight gain, cough, vomiting, fever, joint pain and visual impairment. The degree and duration of these side effects may vary between individuals.

In addition, in rare cases, entrectinib may cause serious adverse reactions. These include pneumonia, dyspnea, pleural effusion, sepsis, pulmonary embolism, respiratory failure and fever. These serious adverse reactions may require urgent treatment and close monitoring.

It is important to emphasize that the incidence and severity of side effects vary depending on factors such as individual differences, drug dosage, and length of use. Some patients may experience mild side effects, while others may experience more serious side effects. Therefore, when using entrectinib, doctors will develop an individualized treatment plan based on the patient's specific conditions, and regularly monitor the patient's physical condition and side effects.

If patients experience any discomfort or suspected side effects while taking entrectinib, they should inform their doctor or pharmacist immediately. They will assess the severity of side effects based on the patient's condition and take appropriate steps to manage and mitigate side effects.